

J&J Maximum Fair Price (“MFP”) Implementation Plan for IPAY 2026

Contents

I. Implementation Plan Overview2

II. Operations Overview 2

III. Good Faith Inquiry (GFI) / Dispute Process Overview 5

IV. Access Information 6

V. Attachments 7

VI. Transition Instructions..... 8

VII. Frequently Asked Questions 9

I. Implementation Plan Overview

The “Maximum Fair Price” (“MFP”) is a government-mandated price established under the Inflation Reduction Act (IRA) that drug manufacturers must offer to eligible individuals under Medicare Part D on selected medicines beginning January 1, 2026. Johnson & Johnson (J&J) is aligning its strategies, systems and workflows to incorporate these new mandated prices, ensure compliance with federal law, and provide Medicare beneficiaries access to the “MFP.” STELARA, USTEKINUMAB (unbranded STELARA), and XARELTO are the “J&J Selected Drugs” for “MFP” effectuation in 2026.

Centers for Medicare and Medicaid Services (CMS) requires that dispensing entities (DEs) register with the Medicare Transaction Facilitator (MTF) Data Module (DM) to receive “MFP” refund payments from J&J beginning in January 2026. DEs can register at <https://mtf.cms.gov/mtfdm/login>.

For additional information about the “Medicare Drug Price Negotiation Program,” please see the following resources from the Centers for Medicare & Medicaid Services (CMS):


- [Medicare Drug Price Negotiation Program Overview](#)
- [Medicare Drug Price Negotiation Program](#): Final Guidance, Implementation of Sections 1191 – 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price in 2026 and 2027
- [Medicare Drug Price Negotiation Program](#): Draft Guidance, Implementation of Sections 1191 – 1198 of the Social Security Act for Initial Price Applicability Year 2028 and Manufacturer Effectuation of the Maximum Fair Price in 2026, 2027, and 2028

II. Operations Overview

A. Process for Effectuation of “MFP,” in accordance with CMS guidance

J&J will use the CMS-provided Medicare Transaction Facilitator (MTF) Data Module (DM) and Payment Module (PM) to effectuate “MFP” for J&J Selected Drugs. The process flow below provides an overview of how J&J will effectuate “MFP” based on CMS final guidance.

Attachment A: High-Level "MFP" Effectuation Process Flow



B. Key Components of Effectuation Process, in accordance with CMS guidance

J&J plans to transmit claim level payment elements to the MTF DM as required by CMS guidance in order to meet the "MFP" payment cycle time (14 days after J&J receives complete claim level detail for eligible claims from the MTF DM). Refer to the timeline below for details on "MFP" claim and refund processing timing.

Attachment B: High-Level Timeline: "MFP" Claim & Refund Processing



CMS: Centers for Medicare & Medicaid Services; DE: Dispensing Entity; DM: Data Module; J&J: Johnson & Johnson; "MFP": "Maximum Fair Price"; MTF: Medicare Transaction Facilitator; PDE: Prescription Drug Event; PM: Payment Module

J&J will use the MTF, as described in CMS guidance, to dispute or offset claims deemed to be ineligible for “MFP.” For example, J&J is not required to pay “MFP” refunds to dispensing entities (DEs) on 340B claims when the 340B price is lower than MFP. In addition, J&J is not required to pay “MFP” refunds in instances where a claim is deemed ineligible for other reasons (duplication, unit of measure error, etc.). J&J will work with DEs on refunds and offsets through the MTF and its provided ledger capabilities.

C. “MFP” Refund Calculation

J&J plans to primarily use the Standard Default Refund Amount (SDRA) set forth in the final guidance to calculate and make the retrospective “MFP” refund payments to a DE.

$$\text{“MFP” refund} = \text{Wholesaler Acquisition Cost (WAC)} - \text{“MFP”}$$

Where contracted otherwise, the “MFP” refund will be calculated using contract price(s) as follows:

$$\text{“MFP” refund} = \text{contract price} - \text{“MFP”}$$

For claims that are also 340B-eligible, if the “MFP” is lower than 340B price, the “MFP” refund will be calculated using the 340B price as follows:

$$\text{“MFP” refund} = \text{340B price} - \text{“MFP”}$$

For claims where the “MFP” refunds are calculated using contract price(s), J&J will retain all claim history including the claim basis price used to calculate the refund and contract(s) which includes the agreed upon contract price(s). For 340B-eligible claims where the “MFP” is less than the 340B price, all claim history will be maintained, including the determination that the claim basis price was used to calculate the refund. The DE will have visibility to the basis of price in a third-party vendor portal called Beacon Channel Management, or “Beacon.”

D. IRA “MFP” 340B Deduplication Policy

JJHCS will participate in the Health Resources & Services Administration’s (HRSA) 340B Rebate Model Pilot Program (Pilot Program) to deduplicate “MFP” and 340B discounts for Part D claims for J&J Selected Drugs available to covered entities through a rebate, as described in the JJHCS 340B rebate model notice available at <https://www.jnj.com/innovativemedicine/us/authorizeddistributors/policies>.

JJHCS’s 340B rebate model will interact with J&J’s “MFP” Implementation Plan by supporting the identification of 340B-eligible dispenses or administrations of J&J Selected Drugs and the prevention of duplicate discounts between 340B and “MFP”.

Identification Process

Following the dispensing or administration of J&J Selected Drugs to covered entity patients, covered entities will submit required 340B rebate claim data to the Beacon platform to request a rebate to realize the 340B ceiling price on a dispense or administration of a J&J Selected Drug. When a 340B rebate claim has been validated and paid, it will be considered an eligible 340B claim for the purposes of “MFP”/340B deduplication.

The validated and paid 340B rebate claims will be matched against “MFP” claims in order to identify instances where an “MFP” refund is requested on a 340B-eligible claim. This duplication may be identified either before or after the “MFP” refund payment is processed due to likely variances in the timing of submission between the 340B rebate claim and the “MFP” refund claim.

In addition to using 340B rebate claims data, “MFP”/340B duplication will also be identified when a 340B modifier is included by the DE on the “MFP” refund claim.

“MFP” Payment Process

If an “MFP” refund claim has been identified on a 340B-eligible claim through the 340B deduplication process, the “MFP” refund will be treated as follows:

- If the “MFP” is lower than the 340B ceiling price, the DE will receive the incremental discount for the amount between the 340B ceiling price and the “MFP”.
- If the 340B ceiling price is lower than the “MFP,” the DE will not receive an “MFP” refund.

If the duplication has been identified after the “MFP” payment has been processed, an adjustment will be performed on the DE’s MTF account using the credit/debit ledger.

INTERIM DEDUPLICATION PROCESS DURING 340B REBATE MODEL PILOT PROGRAM PAUSE

On December 31, 2025, HRSA’s Office of Pharmacy Affairs announced that it is pausing implementation of the Pilot Program for all covered entity types at this time. Until the Pilot Program resumes, J&J will use an interim approach that endeavors to deduplicate “MFP” and 340B discounts on Part D dispenses of J&J Selected Drugs consistent with the IRA.

Only covered entities possess complete data on which drug dispenses are 340B-eligible. In the absence of covered entities providing this data through the Pilot Program, J&J’s interim approach must rely on available data (limited and imperfect) to determine which claims are 340B-eligible. To identify 340B-eligible “MFP” claims for J&J’s selected drugs, consistent with CMS guidance, J&J will take into account, for example: 340B claim modifiers (if included on claims), claims that covered entities self-identify as 340B-eligible using 340B ESP, and evidence of 340B purchasing.

DEs are encouraged to include 340B modifiers on 340B-eligible “MFP” claims, at the time of initial claim submission, to facilitate deduplication with “MFP” refunds. Please see CMS’s “MFP” effectuation guidance for additional information.

Good Faith Inquiries and Certification

If a DE has a question about, or wishes to resolve a discrepancy with, a 340B eligibility determination on an “MFP” claim, the DE should follow the Good Faith Inquiry (GFI) process described below and in the Beacon MFP Resolution Center.

As part of the GFI process, the DE or covered entity may certify that a claim is not 340B-eligible by submitting specified claims data via 340B ESP. Once an inquiry for an “MFP” claim is created, the Beacon MFP Resolution Center will specify the claims data to be submitted. Validated completion of this data submission will trigger a credit/debit ledger adjustment for the “MFP” claim on the DE’s MTF account.

By completing the certification process described above, the DE or covered entity (whichever submits the specified claims data) represents that a final 340B eligibility determination has been made for the “MFP” claim at issue, that such claim is not 340B-eligible, and that the DE or covered entity, as applicable, will promptly notify Beacon MFP and J&J of any subsequent change in 340B eligibility for the claim. J&J reserves all rights to address “MFP” and 340B pricing discrepancies caused by subsequent changes in 340B eligibility of “MFP” claims, including by performing adjustments to the DE’s MTF account using the credit/debit ledger.

III. Good Faith Inquiry (GFI) / Dispute Process Overview

A. Approach to Supporting Good Faith Inquiries (GFIs) and Disputes


CMS encourages DEs and Primary Manufacturers to work together in good faith to resolve any issues regarding “MFP” access. DEs can initiate Good Faith Inquiries (GFIs) related to “MFP” Effectuation with J&J through Beacon.

The Beacon support team is available M-F 9 AM-9 PM ET via chat and phone and DEs can review online support materials or submit inquiries via email at any time. DEs should use the platform to proactively understand the status of claims related to “MFP” effectuation for J&J Selected Drugs. If a DE has further questions, they should refer to the Good Faith Inquiry (GFI) Process or customer support. Note, for “Technical Disputes,” as defined by CMS, the DE should contact CMS directly. The Beacon platform will have “MFP” information available to the DEs, including claim status, submission status, basis of pricing type, and key dates and payment amounts. J&J recommends DEs reference their respective Beacon dashboard prior to submitting an inquiry or dispute.

B. Good Faith Inquiry (GFI) Process

If open questions related to “MFP” effectuation claims for J&J Selected Drugs still remain, a DE can begin the Good Faith Inquiry (GFI) process. A GFI should be submitted via Beacon’s Resolution Center, referencing the ICN (Invoice Control Number). To support the GFI process, DEs may be required to submit documentation to support their inquiry. Following submission of a GFI and supporting documentation, the customer support team will assess the submitted documentation and share a response via Beacon. Reference Attachment C for more details on the GFI process, including for claim-specific and non-claim-specific questions.

Attachment C: Good Faith Inquiry Process Flow



C. Dispute Process

According to [CMS Medicare Drug Price Negotiation Program Guidance](#) (section 90.2.2) published in May 2025, under the “Medicare Drug Price Negotiation Program,” a dispute is “a specific, identifiable challenge to a technical aspect of the MTF system and process (e.g., claims included as potentially requiring an “MFP” refund).”

DEs should submit disputes directly to CMS through the MTF DM using the following CMS final guidance published in May 2025: “The first track is a dispute functionality within the MTF for qualifying disputes from Primary Manufacturers or DEs, and, beginning in 2028, Part B providers regarding a technical aspect of the MTF process...CMS will evaluate disputes and issue findings as appropriate based on available relevant factual information.”

IV. Access Information

Beacon Information

- [Link](#) to Beacon’s “MFP” Platform (**available beginning October 1, 2025**)


CMS Website Information

- For questions related to payment logistics or timing, please visit the CMS website at the following [link](#)

V. Attachments


Attachment A

High-Level "MFP" Effectuation Process Flow



Attachment B


High-Level Timeline: "MFP" Claim & Refund Processing



CMS: Centers for Medicare & Medicaid Services; DE: Dispensing Entity; DM: Data Module; J&J: Johnson & Johnson; "MFP": "Maximum Fair Price"; MTF: Medicare Transaction Facilitator; PDE: Prescription Drug Event; PM: Payment Module

Attachment C

Good Faith Inquiry Process Flow



Attachment D

Additional Available Resources / Webpages

1.	J&J "MFP" Effectuation FAQs (<i>see FAQ section below</i>)
2.	Beacon's "MFP" platform (available beginning October 1, 2025)
3.	CMS Medicare Drug Price Negotiation Program Information

VI. Transition Instructions

For more information about enrollment, please see the CMS provided [Pharmacy and Dispensing Entity Resources](#)

DEs can take the following actions to facilitate "MFP" refunds as quickly as possible:

- Participate in the MTF DM and MTF PM processes as outlined by CMS guidance
- Completely identify all data fields in claim level data
- Ensure only "MFP"-eligible claims are submitted for the "MFP" effectuation process
- Set up the CMS prescribed financial/banking procedure to ensure an automated flow of "MFP" payments from the MTF PM

VII. Frequently Asked Questions

1. When will the “Maximum Fair Price” (“MFP”) take effect and how is Johnson & Johnson preparing to comply with the Inflation Reduction Act (IRA)?

Under the IRA, the “Maximum Fair Price” (“MFP”) is the price ceiling for certain Medicare drugs, as determined by CMS. The first round of selected Part D drugs will have the “MFP” take effect on **January 1, 2026**.

Johnson & Johnson is aligning its systems and workflows to incorporate these new prices, ensure compliance with federal law and provide pharmacies access to the “MFP.”

2. Which Johnson & Johnson Drugs are Affected by “MFP” Effectuation?

XARELTO®, STELARA®, and USTEKINUMAB (unbranded STELARA) are the J&J medicines selected for “MFP” effectuation in 2026.

3. How does the “MFP” program overlap with the 340B program?

If the “Maximum Fair Price” (“MFP”) is lower than the 340B ceiling price, manufacturers must provide access to the “MFP” in a nonduplicated amount to the 340B ceiling price. If the 340B ceiling price is lower than the “MFP,” manufacturers are not required to provide access to the “MFP.” CMS has stated to date that it will not determine 340B eligibility of “MFP” claims, therefore manufacturers must implement processes for identifying 340B-eligible “MFP” claims and deduplicating discounts between “MFP” and 340B.

4. Can you please clarify the role of Beacon?

Johnson & Johnson will use [Beacon’s “MFP” platform](#) (available starting October 1st, 2025), a secure, third-party platform to support DEs in managing “MFP” claims. Through Beacon, users can:

- View real-time updates on submitted claims or issues.
- Access claim details (status, ICN number, invoice date, validated price, basis of price type, applicable WAC/ “MFP”/SDRA pricing).
- Upload supporting documentation for open good faith inquiry cases if applicable.

5. How does Beacon facilitate the effectuation of the “MFP?”

Beacon facilitates the effectuation of the “MFP” by:

- Ingesting and validating refund data received from the MTF DM.
- Management of a system displaying the status of all “MFP” refund requests and payments.
- Communication of “MFP” refund request status back to J&J for submission to the MTF DM.

6. How do I submit a Good Faith Inquiry?

Johnson & Johnson will leverage Beacon’s “MFP” platform to centralize and manage all inquiry submissions, and track and support the Good Faith Inquiry (GFI) process outlined in CMS guidance. Users can initiate a Good Faith Inquiry through the Beacon Resolution Center. All GFI communications are recorded and tracked to ensure transparency and timely resolution.

7. How long does it take to receive an “MFP” refund?

CMS Guidance requires that the Primary Manufacturer must transmit claim-level payment elements to the MTF DM within 14 days after the MTF DM sends claims-level data to the Primary manufacturer. MTF PM will be responsible for issuing payments directly to DEs. J&J will make funds available to the MTF PM within the 14-day timeline, and the MTF PM is then responsible for issuing payments to DEs. We are not aware of how long their payment process may take.

8. What should I do if I believe the “Maximum Fair Price” (“MFP”) refund from Johnson & Johnson is incorrect?

If your entity has concerns about a “Maximum Fair Price” (“MFP”) refund received from Johnson & Johnson, you should submit an inquiry via the Beacon Resolution Center. Beacon’s “MFP” platform offers a centralized, transparent, and efficient process for resolving disputes, addressing refund discrepancies, and managing other issues related to the “MFP” program.

9. What should I do if I have a cash flow concern related to “MFP” implementation?

If you anticipate a significant cash flow concern, follow CMS guidance by reporting it at the start of the initial price applicability year. For questions related to payment logistics or timing, please visit the CMS website at the following [link](#).